Abstract
Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 1999; 10: 1772–1777 13. Donadio JV, Larson TS, Bergstrahl EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12: 791–799 14. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739–1744 15. Lai KN, Lai FM, HO CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174–180 16. Shoji T, Nakanishi I, Suzuki A et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult with diffuse proliferative Iga nephropathy. Am J Kidney Dis 2000; 35: 194–201 17. Katafuchi R, Ikeda K, Mizusama T et al. Controlled prospective trial of steroid treatment in IgA nephropathy: a limitation of lowdose prednisolone therapy. Am J Kidney Dis 2003; 41: 972–983 18. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized controlled trial. J Am Soc Nephrol 2004; 15: 157–163 19. Praga M, Gutierez E, Gonzales E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled study. J Am Soc Nephrol 2003; 14: 1578–1583 20. Woo KY, Edmonson RPS, Yap HK et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1987; 27: 56–64 21. Walker RG, Su SH, Owen JE, Kindkaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103–107 22. Beukhof J, Kardaun O, Schaafsma W et al. Toward individual pronosis of IgA nephropathy. Kidney Int 1986; 29: 549–546 23. Bartosik P, Lajoie G, Sugar L, Cattran D. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728–735
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
